#United States #New York #Clinical Trials #Inato #patient recruitment

Inato's Transformative AI Solution for Clinical Trials

Inato, a pioneering platform dedicated to enhancing clinical trial access and inclusivity, recently revealed a game-changing AI-powered patient pre-screening tool. This innovative feature aims to alleviate the burden on research sites while expediting the patient enrollment process. By incorporating advanced artificial intelligence models, Inato is set to revolutionize a traditionally labor-intensive and time-consuming practice.

The Challenge of Patient Enrollment in Clinical Trials

Patient recruitment has long been identified as a significant roadblock in clinical trials. Current data indicates that the time required for patient enrollment has increased by 25% compared to five years ago. This rise is attributed to greater trial complexity, larger participant numbers, and intensified competition for suitable candidates. These challenges underscore the necessity for innovative solutions to streamline patient identification and review processes, which Inato’s latest AI advancements seek to address.

Introducing AI-Enabled Pre-Screening

As of today, research sites across the United States can implement Inato’s AI-enabled patient pre-screening feature without needing integration with electronic medical records (EMR) or clinical trial management systems (CTMS). The new technology allows for rapid evaluation of patient records, allowing trials to identify eligible candidates within minutes instead of hours. Early adopters have reported time reductions in pre-screening processes by over 50%, with some even noting up to 90% efficiency gains.

Kourosh Davarpanah, Co-founder and CEO of Inato, stated, "Patient recruitment is one of the biggest hurdles in clinical trials. Recent advances in AI reasoning enable sites to identify and review patients at scale—fundamentally changing how they approach this challenge." This sentiment reflects a shift in operational strategy, allowing research sites to enhance patient access to trial options and effectively expedite enrollment timelines.

AI Models That Enhance Efficiency

Inato’s system utilizes an AI agent to carefully review de-identified patient records and quickly determine the relevance of trials to each individual. The AI assesses eligibility based on established inclusion and exclusion criteria, providing swift and accurate assessments in compliance with HIPAA guidelines. The sophisticated algorithms can even interpret medical histories, manage complex parameters, and facilitate medical reasoning.

For instance, consider a trial that necessitates patients with a specified seizure history. The AI combines mathematical evaluations with medical insights to summarize eligibility criteria, rendering complex evaluations simple and efficient for site staff.

Collaboration with Research Sites

Inato has engaged in close collaborations with both trial sponsors and research sites to develop and pilot these new capabilities. The firm’s ongoing partnership with organizations like Pantheon Clinical Research is instrumental in expanding AI functionalities into other phases of trials like feasibility assessments.

Mari Livermore, Site Director and CEO at Pantheon Clinical Research, expressed her enthusiasm for Inato’s advancements, stating, "Inato has completely transformed our patient pre-screening process. It used to take an immense amount of time to evaluate a single patient for a trial. Now, Inato can handle the pre-screening of all our patients across our trials in a fraction of the time."

The Future of Clinical Trials with Inato

Inato empowers research sites to not only identify relevant trials but also to develop compelling applications that highlight their unique capabilities. This transformative approach accelerates patient pre-screening and aids in enhancing site performance in clinical trials.

As Inato leads the way in integrating AI with clinical research, they remain committed to their mission of making clinical trials accessible to every patient, regardless of location. By bridging the gap between research sites, sponsors, and patients, Inato is poised to advance the accessibility and representation of clinical research in the healthcare landscape.

For further insights about patient pre-screening, visit Inato’s website.